A resin most makers will never load into a printer just cleared a hurdle that matters far beyond the hobbyist bench: it regrew cartilage inside a living joint. According to a report from Voxelmatters, researchers at TU Wien printed biodegradable microscaffolds from BIO INX's DEGRAD INX resin, seeded them with cartilage cell spheroids, and implanted them into rabbit knees with critical-sized joint damage. Twelve weeks later, the animals had grown new cartilage reaching roughly 91% of natural thickness — tissue histologists described as "nearly normal." It is, per the report, the first time this particular scaffold strategy has made the jump from a lab dish to a living organism.
If that sounds like a niche biotech footnote, it's worth pausing on the manufacturing method underneath it, because it sits at the far edge of what additive manufacturing can currently do — and it's a useful reminder of how much headroom exists above the resolution most desktop resin printers operate at.
The Technique: Printing Smaller Than a Cell Can See
The scaffolds in this study weren't printed on anything resembling a Form 3 or an Elegoo. The team — led by Prof. Aleksandra Ovsianikov with PhD student Oliver Kopinski-Grünwald, working within the Austrian Cluster for Tissue Regeneration — used multiphoton lithography, a laser-based printing technique capable of resolutions below one micrometer. Desktop MSLA resin printers, by contrast, work in tens of microns of XY pixel pitch, so the gap is measured in orders of magnitude, not increments — achieved by focusing a laser so precisely that polymerization only occurs at the tight point where two photons overlap in space and time, rather than anywhere the beam passes through.
Each finished scaffold was spherical, about 0.3mm in diameter — roughly the size of a grain of sand — and was seeded with spheroids: small, self-organized clusters of cartilage cells grown from stem cells. The spheroids were placed onto the printed scaffolds and allowed to mature before implantation, giving the cells time to establish themselves within the printed architecture rather than being dropped into the joint cold.
This "bottom-up" approach — build a precisely structured scaffold at cell scale, then let biology fill it in — is not new in concept. Academic work such as the bottom-up cartilage tissue engineering research published via Bone & Joint had already established the logic of spheroid-seeded, high-resolution printed scaffolds for cartilage repair, describing scaffolds of the same roughly 300-micrometer diameter, printed with the same two-photon polymerization technique and the same Degrad INX resin, seeded with stem-cell spheroids and fused into larger tissue constructs in the lab. What's new in the rabbit study is that the concept survived contact with an actual immune system, actual joint mechanics, and actual healing biology in a living animal, rather than a petri dish or a bioreactor.
Why the Resin Itself Is the Hard Part
The print resolution is impressive, but the resin chemistry is arguably the harder engineering problem. DEGRAD INX has to satisfy a set of requirements that have nothing to do with the printability and mechanical properties makers usually care about. It needs to photopolymerize cleanly at multiphoton-lithography resolution, hold a stable 3D microstructure while living cells attach and grow on it, and then degrade in the body at a rate that roughly matches the pace at which the cells replace it with their own natural cartilage matrix. Degrade too fast and the scaffold collapses before new tissue can take over; too slow and it becomes a foreign-body obstruction. Getting that degradation window right, inside a resin that also has to be biocompatible and cytocompatible at the print stage, is the kind of formulation work that doesn't show up in a headline but is the actual reason this result took years of lab-dish work — the researchers describe roughly a decade on this micro-scaffold strategy — to reach an animal trial.
The reported outcome — regenerated cartilage at about 91% of natural thickness, assessed histologically as nearly normal — is a meaningfully strong result for cartilage specifically, a tissue notorious in orthopedics for healing poorly on its own because it lacks its own blood supply.
What It Means for Makers
Nobody is printing knee scaffolds on a desktop resin printer, and DEGRAD INX won't show up in a Formlabs or Anycubic materials library. But this result is a useful data point for anyone tracking where photopolymer resin chemistry and micro-scale additive manufacturing are heading, for a few reasons:
Resin engineering is becoming a discipline of its own. The maker community mostly evaluates resins on cure time, shrinkage, and Shore hardness. DEGRAD INX is a reminder that the same base technology — light-cured photopolymer chemistry — is being pushed toward application-specific formulations with entirely different success criteria, in this case, controlled biodegradation timed to cell biology. The chemistry toolkit is shared; the design goals diverge wildly by field.
Multiphoton lithography is the resolution ceiling worth knowing about. For hobbyists chasing finer detail on MSLA printers, it's worth knowing that sub-micrometer resolution already exists commercially in the multiphoton lithography space — it's just priced and scaled for research labs and medtech, not desktops. It's the same broad family of light-based additive manufacturing, at a resolution and cost point several rungs up the ladder.
Medical AM keeps validating the "print a scaffold, let biology finish the job" model. This isn't printing a replacement part — it's printing temporary infrastructure that a living system populates and eventually replaces entirely. That's a distinct manufacturing philosophy from anything in mechanical or aesthetic 3D printing, and it's increasingly where some of the most technically demanding print work is happening.
The practical upside the researchers themselves point to, per Voxelmatters, is a future where these scaffolds could potentially be injected to fill irregular cartilage defects without opening the joint, with cell-loaded building blocks delivered into the damaged area to adapt to the shape of the defect — turning an invasive procedure into something closer to a minimally invasive injection. That's still down the road; a rabbit-knee study, however successful, is a preclinical milestone, not a clinical one. Human trials, regulatory approval, and scale-up all sit ahead of it. But going from lab dish to living joint, with tissue that reads as "nearly normal" under a microscope, is the kind of step that tends to unlock the next round of funding and follow-on research — which is exactly the point at which technologies like this start being worth watching.
